Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.38 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404780 | 0.86 | GBA1 (0.49) | GBA1GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2401844 | 0.85 | LMNA (0.37) | GBA1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2403233 | 0.81 | GBA1 (0.53) | GBA1GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2404794 | 0.79 | CKS1B (0.42) | GBA1GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2404593 | 0.75 | PTPN11 (0.59) | GBA1GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2401936 | 0.70 | HTT (0.40) | GBA1POLBMEN1KMT2AMAPT | |
| SCHEMBL2386105 | 0.69 | GBA1 (0.54) | GBA1GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2401761 | 0.69 | GBA1 (0.54) | GBA1GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2274835 | 0.69 | GBA1 (0.55) | GBA1GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2405697 | 0.69 | NR1H2 (0.42) | GBA1GPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | GBA1 1531/4885GPR119 188/4885CKS1B 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.